FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Hicklin

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Neovascularization, Pathologic

Procedures

Anatomy

Physiology

Signal Transduction

Co-author Network

Publications

TOP 3
James R Tonra; Erik Corcoran; Dhanvanthri S Deevi; Philipp Steiner; Jessica Kearney; Huiling Li; Dale L Ludwig; Zhenping Zhu; Larry Witte; David Surguladze; Daniel J Hicklin
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
James R Tonra; Marie Prewett; Erik Corcoran; Daniel J Hicklin; Zhenping Zhu
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
Lee M Ellis; Daniel J Hicklin
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Hicklin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: James R Tonra; Erik Corcoran; Dhanvanthri S Deevi; Philipp Steiner; Jessica Kearney; Huiling Li; Dale L Ludwig; Zhenping Zhu; Larry Witte; David Surguladze; Daniel J Hicklin
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
Anticancer research 2009;29(6):1999-2007.
2009: James R Tonra; Marie Prewett; Erik Corcoran; Daniel J Hicklin; Zhenping Zhu
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
Methods in molecular biology (Clifton, N.J.) 2009;525():545-57, xv.
2008: Lee M Ellis; Daniel J Hicklin
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6371-5.
2008: Dipa Patel; Rajiv Bassi; Andrea T Hooper; Haijun Sun; James Huber; Daniel J Hicklin; Xiaoqiang Kang
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.
Anticancer research 2008;28(5A):2679-86.
2008: Lee M Ellis; Daniel J Hicklin
VEGF-targeted therapy: mechanisms of anti-tumour activity.
Nature reviews. Cancer 2008;8(8):579-91.
2008: George van Buren; Anthony D Yang; Nikolaos A Dallas; Michael J Gray; Sherry J Lim; Ling Xia; Fan Fan; Ray Somcio; Yan Wu; Daniel J Hicklin; Lee M Ellis
Effect of molecular therapeutics on liver regeneration in a murine model.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(11):1836-42.
2008: Marzia Scortegagna; Christophe Cataisson; Rebecca J Martin; Daniel J Hicklin; Robert D Schreiber; Stuart H Yuspa; Jeffrey M Arbeit
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling.
Blood 2008;111(7):3343-54.
2008: Christine H Chung; Beloo Mirakhur; Emily Chan; Quynh-Thu Le; Jordan Berlin; Michael Morse; Barbara A Murphy; Shama M Satinover; Jacob Hosen; David Mauro; Robbert J Slebos; Qinwei Zhou; Diane Gold; Tina Hatley; Daniel J Hicklin; Thomas A E Platts-Mills
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
The New England journal of medicine 2008;358(11):1109-17.
2007: Oliver Stoeltzing; Wenbiao Liu; Fan Fan; Christine Wagner; Kathrin Stengel; Ray Somcio; Niels Reinmuth; Alexander A Parikh; Daniel J Hicklin; Lee M Ellis
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.
Cancer letters 2007;258(2):291-300.
2007: Marie Prewett; Dhanvanthri S Deevi; Rajiv Bassi; Fan Fan; Lee M Ellis; Daniel J Hicklin; James R Tonra
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7432-40.
2007: Jacqueline F Doody; Ying Wang; Sheetal N Patel; Christopher Joynes; Sui Ping Lee; Jason Gerlak; Robin L Rolser; Yanxia Li; Philipp Steiner; Rajiv Bassi; Daniel J Hicklin; Yaron R Hadari
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.
Molecular cancer therapeutics 2007;6(10):2642-51.
2007: Hagop Youssoufian; Daniel J Hicklin; Eric K Rowinsky
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5544s-5548s.
2007: Dipa Patel; Armin Lahiji; Sheetal Patel; Matthew Franklin; Xenia Jimenez; Daniel J Hicklin; Xiaoqiang Kang
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.
Anticancer research 2007;27(5A):3355-66.
2007: Zhichao Zhou; Marcela F Bolontrade; Krishna Reddy; Xiaoping Duan; Hui Guan; Ling Yu; Daniel J Hicklin; Eugenie S Kleinerman
Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4867-73.
2007: Alison M Y Cheung; Allison S Brown; Viviene Cucevic; Marcia Roy; Andrew Needles; Victor Yang; Daniel J Hicklin; Robert S Kerbel; F Stuart Foster
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
Ultrasound in medicine & biology 2007;33(8):1259-68.
2007: Elizabeth A Manning; John G M Ullman; James M Leatherman; Justin M Asquith; Timothy R Hansen; TD Armstrong; Daniel J Hicklin; Elizabeth M Jaffee; Leisha A Emens
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3951-9.
2007: Sergey V Kozin; Frank Winkler; Igor Garkavtsev; Daniel J Hicklin; Rakesh K Jain; Yves Boucher
Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
Cancer research 2007;67(11):5076-82.
2007: Jens Gille; Regina Heidenreich; Andreas Pinter; Judith Schmitz; Beatrice Boehme; Daniel J Hicklin; Reinhard Henschler; Georg Breier
Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation.
International journal of cancer. Journal international du cancer 2007;120(9):1899-908.
2007: Chris Folkins; Shan Man; Ping Xu; Yuval Shaked; Daniel J Hicklin; Robert S Kerbel
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Cancer research 2007;67(8):3560-4.
2007: Vincent Laudenbach; Romain H Fontaine; Fadia Medja; Peter Carmeliet; Daniel J Hicklin; Jorge Gallego; Philippe Leroux; Stéphane Marret; Pierre Gressens
Neonatal hypoxic preconditioning involves vascular endothelial growth factor.
Neurobiology of disease 2007;26(1):243-52.
2007: Olivier Raisky; Antti I Nykänen; Rainer Krebs; Maria Hollmén; Mikko A I Keränen; Jussi M Tikkanen; Roope K Sihvola; Leena Alhonen; Petri Salven; Yan Wu; Daniel J Hicklin; Kari Alitalo; Petri K Koskinen; Karl B Lemström
VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(4):819-25.
2007: Jeremy Goldman; Joseph M Rutkowski; Jacqueline D Shields; Miriella C Pasquier; Yingjie Cui; Hugo Schmökel; Stephen Willey; Daniel J Hicklin; Bronislaw Pytowski; Melody Swartz
Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(4):1003-12.
2007: Ernest Ramsay Camp; Anthony Yang; Michael J Gray; Fan Fan; Stanley R Hamilton; Douglas B Evans; Andrea T Hooper; Daniel S Pereira; Daniel J Hicklin; Lee M Ellis
Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Cancer 2007;109(6):1030-9.
2007: Daniel J Hicklin
Promoting angiogenesis to a fault.
Nature biotechnology 2007;25(3):300-2.
2007: Philipp Steiner; Christopher Joynes; Rajiv Bassi; Su Wang; James R Tonra; Yaron R Hadari; Daniel J Hicklin
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(5):1540-51.
2007: Gregory W Allen; Corey Saba; Eric A Armstrong; Shyh-Min Huang; Sergio Benavente; Dale L Ludwig; Daniel J Hicklin; Paul M Harari
Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Cancer research 2007;67(3):1155-62.
2007: Pirjo Laakkonen; Marika Waltari; Tanja Holopainen; Takashi Takahashi; Bronislaw Pytowski; Philipp Steiner; Daniel J Hicklin; Kris Persaud; James R Tonra; Larry Witte; Kari Alitalo
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Cancer research 2007;67(2):593-9.
2007: Dipa Patel; Paul Balderes; Armin Lahiji; Maxine Melchior; Stanley Ng; Rajiv Bassi; Yan Wu; Heather Griffith; Xenia Jimenez; Dale L Ludwig; Daniel J Hicklin; Xiaoqiang Kang
Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
Human antibodies 2007;16(3-4):127-36.
2007: James R Tonra; Daniel J Hicklin
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
Immunological investigations 2007;36(1):3-23.
2006: Rainer Krebs; Maria Hollmén; Jussi M Tikkanen; Y Wu; Daniel J Hicklin; Petri K Koskinen; Karl B Lemström
Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.
Transplantation proceedings 2006;38(10):3266-7.
2006: Yan Wu; Zhaojing Zhong; James Huber; Rajiv Bassi; Bridget Finnerty; Erik Corcoran; Huiling Li; Elizabeth Navarro; Paul Balderes; Xenia Jimenez; Henry Koo; Venkata R M Mangalampalli; Dale L Ludwig; James R Tonra; Daniel J Hicklin
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6573-84.
2006: Yan Wu; Andrea T Hooper; Zhaojing Zhong; Larry Witte; Peter Bohlen; Shahin Rafii; Daniel J Hicklin
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
International journal of cancer. Journal international du cancer 2006;119(7):1519-29.
2006: Yuval Shaked; Alessia Ciarrocchi; Marcela Franco; Christina Lee; Shan Man; Alison M Cheung; Daniel J Hicklin; David Chaplin; F Stuart Foster; Robert Benezra; Robert S Kerbel
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Science (New York, N.Y.) 2006;313(5794):1785-7.
2006: Jennifer M O'Toole; Karen E Rabenau; Kerri Burns; Dan Lu; Venkata R M Mangalampalli; Paul Balderes; Nicole Covino; Rajiv Bassi; Marie Prewett; Kimberly J Gottfredsen; Megan N Thobe; Yuan Cheng; Yiwen Li; Daniel J Hicklin; Zhenping Zhu; Susan E Waltz; Michael J Hayman; Dale L Ludwig; Daniel S Pereira
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
Cancer research 2006;66(18):9162-70.
2006: Lianglin Zhang; Jonathan A F Hannay; Juehui Liu; Parimal Das; Maocheng Zhan; Theresa Nguyen; Daniel J Hicklin; Dihua Yu; Raphael E Pollock; Dina lev
Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
Cancer research 2006;66(17):8770-8.
2006: Donald P Lesslie; Justin M Summy; Nila U Parikh; Fan Fan; Jose G Trevino; Tomi K Sawyer; Chester A Metcalf; William C Shakespeare; Daniel J Hicklin; Lee M Ellis; Gary E Gallick
Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.
British journal of cancer 2006;94(11):1710-7.
2006: Irina Petrache; IWONA FIJALKOWSKA-GORZKA; Lijie Zhen; Terry R Medler; Emile Brown; Pedro Cruz; Kang-Hyeon Choe; Laimute Taraseviciene-Stewart; Robertas Scerbavicius; Lee Shapiro; Bing Zhang; Sihong Song; Daniel J Hicklin; Norbert F Voelkel; Terence Flotte; Rubin M Tuder
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema.
American journal of respiratory and critical care medicine 2006;173(11):1222-8.
2006: Obdulio Piloto; Bao Nguyen; David L Huso; Kyu-Tae Kim; Yiwen Li; Larry Witte; Daniel J Hicklin; Patrick Brown; Donald Small
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Cancer research 2006;66(9):4843-51.
2006: David K Jin; Koji Shido; Hans-Georg Kopp; Isabelle Petit; Sergey V Shmelkov; Lauren M Young; Andrea T Hooper; Hideki Amano; Scott T Avecilla; Beate Heissig; Koichi Hattori; Fan Zhang; Daniel J Hicklin; Yan Wu; Zhenping Zhu; Ashley Dunn; Hassan Salari; Zena Werb; Neil R Hackett; Helen-Ann Brown Epstein; David Lyden; Shahin Rafii
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Nature medicine 2006;12(5):557-67.
2006: Sharon A McGrath-Morrow; Cecilia Cho; Roshni R Molls; Melissa J Burne-Taney; Mark Haas; Daniel J Hicklin; Rubin M Tuder; Hamid Rabb
VEGF receptor 2 blockade leads to renal cyst formation in mice.
Kidney international 2006;69(10):1741-8.
2006: Ernest Ramsay Camp; Anthony Yang; Wenbiao Liu; Fan Fan; Ray Somcio; Daniel J Hicklin; Lee M Ellis
Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2628-33.
2006: James R Tonra; Dhanvanthri S Deevi; Erik Corcoran; Huiling Li; Su Wang; Francine E Carrick; Daniel J Hicklin
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2197-207.
2006: Marcela Franco; Shan Man; Limor Chen; Urban Emmenegger; Yuval Shaked; Alison M Cheung; Allison S Brown; Daniel J Hicklin; F Stuart Foster; Robert S Kerbel
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Cancer research 2006;66(7):3639-48.
2006: Jeanne M du Manoir; Giulio Francia; Shan Man; Miriam Mossoba; Jeffrey A Medin; Alicia Viloria-Petit; Daniel J Hicklin; Urban Emmenegger; Robert S Kerbel
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):904-16.
2006: Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David B Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; José Baselga; Neal Rosen
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer research 2006;66(3):1500-8.
2006: Anthony D Yang; Ernest Ramsay Camp; Fan Fan; Lanlan Shen; Michael J Gray; Wenbiao Liu; Ray Somcio; Todd W. Bauer; Yan Wu; Daniel J Hicklin; Lee M Ellis
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.
Cancer research 2006;66(1):46-51.
2005: Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott Kerns; Zhenping Zhu; Daniel J Hicklin; Yan Wu; Jeffrey L Port; Nasser K Altorki; Elisa Rush Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
Nature 2005;438(7069):820-7.
2005: Wenbiao Liu; Alexander A Parikh; Oliver Stoeltzing; Fan Fan; Marya F McCarty; Jane S Wey; Daniel J Hicklin; Lee M Ellis
Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF.
Cytokine 2005;32(5):206-12.
2005: Yuichi Ohki; Beate Heissig; Yayoi Sato; Haruyo Akiyama; Zhenping Zhu; Daniel J Hicklin; Kazunori Shimada; Hideoki Ogawa; Hiroyuki Daida; Koichi Hattori; Akimichi Ohsaka
Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(14):2005-7.
2005: Yuval Shaked; Guido Bocci; Raquel Munoz; Shan Man; John M L Ebos; Daniel J Hicklin; Francesco Bertolini; Robert D'Amato; Robert S Kerbel
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.
Current cancer drug targets 2005;5(7):551-9.
2005: Daniel W Miller; Silvia Vosseler; Nicolae Mirancea; Daniel J Hicklin; Peter Bohlen; Hans E Völcker; Frank G Holz; Norbert E Fusenig
Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.
The American journal of pathology 2005;167(5):1389-403.
2005: Loïc Vincent; Pouneh Kermani; Lauren M Young; Joseph Cheng; Fan Zhang; Koji Shido; George Lam; Heidi Bompais-Vincent; Zhenping Zhu; Daniel J Hicklin; Peter Bohlen; David J Chaplin; Chad May; Shahin Rafii
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
The Journal of clinical investigation 2005;115(11):2992-3006.
2005: Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
Cancer cell 2005;8(4):299-309.
2005: Masayuki Sho; Satoru Akashi; Hiromichi Kanehiro; Kaoru Hamada; Hisanori Kashizuka; Naoya Ikeda; Takeo Nomi; Yukiyasu Kuzumoto; Yoshikazu Tsurui; Hitoshi Yoshiji; Yan Wu; Daniel J Hicklin; David M Briscoe; Yoshiyuki Nakajima
Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo.
Transplantation 2005;80(6):717-22.
2005: Beate Heissig; Shahin Rafii; Haruyo Akiyama; Yuichi Ohki; Yayoi Sato; Tejada Rafael; Zhenping Zhu; Daniel J Hicklin; Ko Okumura; Hideoki Ogawa; Zena Werb; Koichi Hattori
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization.
The Journal of experimental medicine 2005;202(6):739-50.
2005: Jane S Wey; Fan Fan; Michael J Gray; Todd W. Bauer; Marya F McCarty; Ray Somcio; Wenbiao Liu; Douglas B Evans; Yan Wu; Daniel J Hicklin; Lee M Ellis
Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
Cancer 2005;104(2):427-38.
2005: Li Ma; Giulio Francia; Alicia Viloria-Petit; Daniel J Hicklin; Jeanne M du Manoir; Janusz Rak; Robert S Kerbel
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Cancer research 2005;65(12):5365-73.
2005: Chad May; Jacqueline F Doody; Rashed Abdullah; Paul Balderes; Xiaohong Xu; Chien Peter Chen; Zhenping Zhu; Lawrence Shapiro; Paul Kussie; Daniel J Hicklin; Fang Liao; Peter Bohlen
Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.
Blood 2005;105(11):4337-44.
2005: Dan Lu; Haifan Zhang; Henry Koo; James R Tonra; Paul Balderes; Marie Prewett; Erik Corcoran; Venkata R M Mangalampalli; Rajiv Bassi; Deborah Anselma; Dipa Patel; Xiaoqiang Kang; Dale L Ludwig; Daniel J Hicklin; Peter Bohlen; Larry Witte; Zhenping Zhu
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
The Journal of biological chemistry 2005;280(20):19665-72.
2005: Sharon A McGrath-Morrow; Cecilia Cho; Chung Cho; Lijie Zhen; Daniel J Hicklin; Rubin M Tuder
Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development.
American journal of respiratory cell and molecular biology 2005;32(5):420-7.
2005: Loïc Vincent; David K Jin; Matthias A Karajannis; Koji Shido; Andrea T Hooper; William K Rashbaum; Bronislaw Pytowski; Yan Wu; Daniel J Hicklin; Zhenping Zhu; Peter Bohlen; Ruben Niesvizky; Shahin Rafii
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
Cancer research 2005;65(8):3185-92.
2005: Fan Fan; Jane S Wey; Marya F McCarty; Anna Belcheva; Wenbiao Liu; Todd W. Bauer; Ray Somcio; Yan Wu; Andrea T Hooper; Daniel J Hicklin; Lee M Ellis
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.
Oncogene 2005;24(16):2647-53.
2005: Nick Loizos; Yan Xu; Jim Huber; Meilin Liu; Dan Lu; Bridget Finnerty; Robin L Rolser; Asra Malikzay; Anita Persaud; Erik Corcoran; Dhanvanthri S Deevi; Paul Balderes; Rajiv Bassi; Xenia Jimenez; Christopher Joynes; Venkata R M Mangalampalli; Philipp Steiner; James R Tonra; Yan Wu; Daniel S Pereira; Zhenping Zhu; Dale L Ludwig; Daniel J Hicklin; Peter Bohlen; Larry Witte; Paul Kussie
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
Molecular cancer therapeutics 2005;4(3):369-79.
2005: Obdulio Piloto; Mark Levis; David L Huso; Yiwen Li; Hongli Li; Mei-Nai Wang; Rajiv Bassi; Paul Balderes; Dale L Ludwig; Larry Witte; Zhenping Zhu; Daniel J Hicklin; Donald Small
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
Cancer research 2005;65(4):1514-22.
2005: Daniel J Hicklin; Lee M Ellis
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(5):1011-27.
2005: Peter Baluk; Tuomas Tammela; Erin Ator; Natalya Lyubynska; Marc G Achen; Daniel J Hicklin; Michael Jeltsch; Tatiana V Petrova; Bronislaw Pytowski; Steven A Stacker; Seppo Ylä-Herttuala; David G Jackson; Kari Alitalo; Donald M McDonald
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.
The Journal of clinical investigation 2005;115(2):247-57.
2005: Bronislaw Pytowski; Jeremy Goldman; Kris Persaud; Yan Wu; Larry Witte; Daniel J Hicklin; Mihaela Skobe; Kendrick C Boardman; Melody Swartz
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Journal of the National Cancer Institute 2005;97(1):14-21.
2005: Hideaki Watanabe; Adam J Mamelak; Elliot Weiss; Binghe Wang; Irwin Freed; Angela K Brice; Lynn M Wachtman; Kathleen L Gabrielson; Naoko Yokota; Daniel J Hicklin; Robert S Kerbel; Mark Haas; Daniel N Sauder
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):407-9.
2005: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Cancer cell 2005;7(1):101-11.
2005: Jorge L Eller; Sharon L Longo; Michele M Kyle; Daniel Bassano; Daniel J Hicklin; Gregory W Canute
Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.
Neurosurgery 2005;56(1):155-62; discussion 162.
2004: Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer cell 2004;6(6):553-63.
2004: Andrew R Reynolds; Louise E Reynolds; Tobi E Nagel; Julie C Lively; Stephen D Robinson; Daniel J Hicklin; Sarah C Bodary; Kairbaan M Hodivala-Dilke
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
Cancer research 2004;64(23):8643-50.
2004: Hideaki Watanabe; Adam J Mamelak; Binghe Wang; Brandon G Howell; Irwin Freed; Clemens Esche; Masashi Nakayama; Go Nagasaki; Daniel J Hicklin; Robert S Kerbel; Daniel N Sauder
Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity.
Experimental dermatology 2004;13(11):671-81.
2004: Stephen D Robinson; Louise E Reynolds; Lorenza Wyder; Daniel J Hicklin; Kairbaan M Hodivala-Dilke
Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(11):2108-14.
2004: Eunice S Wang; Julie T Feldstein; Yan Wu; Zhenping Zhu; Daniel J Hicklin; Malcolm A S Moore
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
Blood 2004;104(9):2893-902.
2004: Ingrid Nilsson; Charlotte Rolny; Yan Wu; Bronislaw Pytowski; Daniel J Hicklin; Kari Alitalo; Lena Claesson-Welsh; Stefan Wennström
Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(13):1507-15.
2004: Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Cancer research 2004;64(18):6616-25.
2004: Haifan Zhang; Yiwen Li; Hongli Li; Rajiv Bassi; Xenia Jimenez; Larry Witte; Peter Bohlen; Daniel J Hicklin; Zhenping Zhu
Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
Leukemia & lymphoma 2004;45(9):1887-97.
2004: Yiwen Li; Hongli Li; Mei-Nai Wang; Dan Lu; Rajiv Bassi; Yan Wu; Haifan Zhang; Paul Balderes; Dale L Ludwig; Bronislaw Pytowski; Paul Kussie; Obdulio Piloto; Donald Small; Peter Bohlen; Larry Witte; Zhenping Zhu; Daniel J Hicklin
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
Blood 2004;104(4):1137-44.
2004: Rainer Kunstfeld; Satoshi Hirakawa; Young Kwon Hong; Vivien Schacht; Bernhard Lange-Asschenfeldt; Paula Velasco; Charles Lin; Edda Fiebiger; Xunbin Wei; Yan Wu; Daniel J Hicklin; Peter Bohlen; Michael Detmar
Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia.
Blood 2004;104(4):1048-57.
2004: Alexander L Rakhmilevich; Andrea T Hooper; Daniel J Hicklin; Paul M Sondel
Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Molecular cancer therapeutics 2004;3(8):969-76.
2004: Darren W Davis; Keiji Inoue; Colin P N Dinney; Daniel J Hicklin; James L Abbruzzese; David J McConkey
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Cancer research 2004;64(13):4601-10.
2004: John M L Ebos; Guido Bocci; Shan Man; Philip E Thorpe; Daniel J Hicklin; Danielle Zhou; Xiaohong Jia; Robert S Kerbel
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Molecular cancer research : MCR 2004;2(6):315-26.
2004: Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; Yan Wu; Koji Yanase; Tadashi Namisaki; Mitsuteru Kitade; Masaharu Yamazaki; Hirohisa Tsujinoue; Tsutomu Masaki; Hiroshi Fukui
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.
Hepatology (Baltimore, Md.) 2004;39(6):1517-24.
2004: Urban Emmenegger; Shan Man; Yuval Shaked; Giulio Francia; John Wong; Daniel J Hicklin; Robert S Kerbel
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Cancer research 2004;64(11):3994-4000.
2004: Ricky T Tong; Yves Boucher; Sergey V Kozin; Frank Winkler; Daniel J Hicklin; Rakesh K Jain
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.
Cancer research 2004;64(11):3731-6.
2004: Peetra Magnusson; Charlotte Rolny; Lars Jakobsson; Charlotte Wikner; Yan Wu; Daniel J Hicklin; Lena Claesson-Welsh
Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development.
Journal of cell science 2004;117(Pt 8):1513-23.
2004: Dale L Ludwig; Larry Witte; Daniel J Hicklin; Marie Prewett; Rajiv Bassi; Douglas Burtrum; Daniel S Pereira; Xenia Jimenez; Floyd Fox; Babita Saxena; Qinwei Zhou; Yuemei Ma; Xiaoqiang Kang; Dipa Patel; Michael Barry; Paul Kussie; Zhenping Zhu; Douglas A Russell; William L Petersen; Thomas P Jury; Fernando Gaitan-Gaitan; Daniel L Moran; Xavier Delannay; Bradley S Storrs; Jacob Tou; Mark E Zupec; Karen S Gustafson; John McIntyre; S Joseph Tarnowski; Peter Bohlen
Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
Human antibodies 2004;13(3):81-90.
2004: Scott T Avecilla; Koichi Hattori; Beate Heissig; Rafael Tejada; Fang Liao; Koji Shido; David K Jin; Sergio Dias; Fan Zhang; Travis E Hartman; Neil R Hackett; Helen-Ann Brown Epstein; Larry Witte; Daniel J Hicklin; Peter Bohlen; Dan Eaton; David Lyden; Frederic J de Sauvage; Shahin Rafii
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.
Nature medicine 2004;10(1):64-71.
2004: Rui Zheng; Mark Levis; Obdulio Piloto; Patrick Brown; Brenda R Baldwin; Norbert-Claude Gorin; Miloslav Beran; Zhenping Zhu; Dale Ludwig; Daniel J Hicklin; Larry Witte; Yiwen Li; Donald Small
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Blood 2004;103(1):267-74.
2003: Douglas Burtrum; Zhenping Zhu; Dan Lu; Donna Marie Anderson; Marie Prewett; Daniel S Pereira; Rajiv Bassi; Rashed Abdullah; Andrea T Hooper; Henry Koo; Xenia Jimenez; Danielle Johnson; Robin Apblett; Paul Kussie; Peter Bohlen; Larry Witte; Daniel J Hicklin; Dale L Ludwig
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Cancer research 2003;63(24):8912-21.
2003: Dale L Ludwig; Daniel S Pereira; Zhenping Zhu; Daniel J Hicklin; Peter Bohlen
Monoclonal antibody therapeutics and apoptosis.
Oncogene 2003;22(56):9097-106.
2003: Yiwen Li; Peter Bohlen; Daniel J Hicklin
Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy.
Current molecular medicine 2003;3(8):773-9.
2003: Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; Y Wu; Koji Yanase; Tadashi Namisaki; Masaharu Yamazaki; Hirohisa Tsujinoue; Hiroo Imazu; Tsutomu Masaki; Hiroshi Fukui
Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.
Gut 2003;52(9):1347-54.
2003: Monica Autiero; Johannes Waltenberger; David Communi; Andrea Kranz; Lieve Moons; Diether Lambrechts; Jens Kroll; Stephane Plaisance; Maria De Mol; Françoise Bono; Stefanie Kliche; Guido Fellbrich; Kurt Ballmer-Hofer; Domenico Maglione; Ulrike Mayr-Beyrle; Mieke Dewerchin; Saskia Dombrowski; Danica Stanimirovic; Paul van Hummelen; Christoph Dehio; Daniel J Hicklin; Graziella Persico; Jean-Marc Herbert; David Communi; Masabumi Shibuya; Désiré Collen; Edward M Conway; Peter Carmeliet
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
Nature medicine 2003;9(7):936-43.
2003: Jean-Christophe Tille; Xueyan Wang; Kenneth E Lipson; Gerald McMahon; Napoleone Ferrara; Zhenping Zhu; Daniel J Hicklin; Jonathan P Sleeman; Ulf Eriksson; Kari Alitalo; Michael S Pepper
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro.
Experimental cell research 2003;285(2):286-98.
2003: Morihisa Akagi; M Kawaguchi; Wenbiao Liu; Marya F McCarty; A Takeda; Fan Fan; Oliver Stoeltzing; Alexander A Parikh; Young D Jung; Corazon D Bucana; P F Mansfield; Daniel J Hicklin; Lee M Ellis
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.
British journal of cancer 2003;88(5):796-802.
2003: Yotaro Izumi; Emmanuelle di Tomaso; Andrea Hooper; Peigen Huang; James Huber; Daniel J Hicklin; Dai Fukumura; Rakesh K Jain; Herman D Suit
Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts.
Cancer research 2003;63(4):747-51.
2002: Donald J Buchsbaum; James A. Bonner; William E Grizzle; Murray A Stackhouse; Mark Carpenter; Daniel J Hicklin; Peter Bohlen; Kevin P Raisch
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
International journal of radiation oncology, biology, physics 2002;54(4):1180-93.
2002: Christiane J Bruns; Marissa Shrader; Matthew T Harbison; Charles Portera; Carmen C Solorzano; K-W Jauch; Daniel J Hicklin; Robert Radinsky; Lee M Ellis
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
International journal of cancer. Journal international du cancer 2002;102(2):101-8.
2002: Jorge L Eller; Sharon L Longo; Daniel J Hicklin; Gregory W Canute
Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Neurosurgery 2002;51(4):1005-13; discussion 1013-4.
2002: Paul Sweeney; Takashi Karashima; Sun-Jin Kim; Daniel Kedar; Badar M Mian; Samuel Huang; Cheryl Baker; Zhen Fan; Daniel J Hicklin; Curtis A Pettaway; Colin P N Dinney
Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2714-24.
2002: Monica Corada; Lucia Zanetta; Fabrizio Orsenigo; Ferruccio Breviario; Maria Grazia Lampugnani; Sergio Bernasconi; Fang Liao; Daniel J Hicklin; Peter Bohlen; Elisabetta Dejana
A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability.
Blood 2002;100(3):905-11.
2002: Koichi Hattori; Beate Heissig; Yan Wu; Sergio Dias; Rafael Tejada; Barbara Ferris; Daniel J Hicklin; Zhenping Zhu; Peter Bohlen; Larry Witte; Jan Hendrikx; Neil R Hackett; Helen-Ann Brown Epstein; Malcolm A S Moore; Zena Werb; David Lyden; Shahin Rafii
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment.
Nature medicine 2002;8(8):841-9.
2002: Aernout Luttun; Marc Tjwa; Lieve Moons; Yan Wu; Anne Angelillo-Scherrer; Fang Liao; Janice A Nagy; Andrea Hooper; Josef Priller; Bert De Klerck; Veerle Compernolle; Evis Daci; Peter Bohlen; Mieke Dewerchin; Jean-Marc Herbert; Roy Fava; Patrick Matthys; Geert Carmeliet; Désiré Collen; Harold F Dvorak; Daniel J Hicklin; Peter Carmeliet
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
Nature medicine 2002;8(8):831-40.
2002: Yiwen Li; Mei-Nai Wang; Hongli Li; Karen D King; Rajiv Bassi; Haijun Sun; Angel Santiago; Andrea T Hooper; Peter Bohlen; Daniel J Hicklin
Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.
The Journal of experimental medicine 2002;195(12):1575-84.
2002: Shan Man; Guido Bocci; Giulio Francia; Shane K Green; Serge Jothy; Douglas Hanahan; Peter Bohlen; Daniel J Hicklin; Gabriele Bergers; Robert S Kerbel
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Cancer research 2002;62(10):2731-5.
2002: Young D Jung; P F Mansfield; M Akagi; A Takeda; Wenbiao Liu; Corazon D Bucana; Daniel J Hicklin; Lee M Ellis
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1133-40.
2002: Takashi Karashima; Paul Sweeney; Joel W Slaton; Sun J Kim; Daniel Kedar; Jonathan I Izawa; Zhen Fan; Curtis A Pettaway; Daniel J Hicklin; Taro Shuin; Colin P N Dinney
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1253-64.
2002: Marie Prewett; Andrea T Hooper; Rajiv Bassi; Lee M Ellis; Harlan W Waksal; Daniel J Hicklin
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):994-1003.
2002: Fang Liao; Jacqueline F Doody; Jay Overholser; Bridget Finnerty; Rajiv Bassi; Yan Wu; Elisabetta Dejana; Paul Kussie; Peter Bohlen; Daniel J Hicklin
Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Cancer research 2002;62(9):2567-75.
2002: Lianglin Zhang; Dihua Yu; Daniel J Hicklin; Jonathan A F Hannay; Lee M Ellis; Raphael E Pollock
Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Cancer research 2002;62(7):2034-42.
2002: Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Daniel J Hicklin; James Huber; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Hiroo Imazu; Hiroshi Fukui
Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 2002;35(4):834-42.
2002: Joanne L Yu; Janusz Rak; Brenda L Coomber; Daniel J Hicklin; Robert S Kerbel
Effect of p53 status on tumor response to antiangiogenic therapy.
Science (New York, N.Y.) 2002;295(5559):1526-8.
2002: Ingeborg Stalmans; Yin-Shan Ng; Richard M Rohan; Marcus Fruttiger; Ann Bouché; Ali Yuce; Hajime Fujisawa; Bart Hermans; Moshe Shani; Sandra Jansen; Daniel J Hicklin; David J Anderson; Tom Gardiner; Hans-Peter Hammes; Lieve Moons; Mieke Dewerchin; Désiré Collen; Peter Carmeliet; Patricia A D'Amore
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.
The Journal of clinical investigation 2002;109(3):327-36.
2002: Giannoula Klement; Ping Huang; Barbara Mayer; Shane K Green; Shan Man; Peter Bohlen; Daniel J Hicklin; Robert S Kerbel
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):221-32.
2001: David Lyden; K Hattori; Sergio Dias; C Costa; Pamela Blaikie; Linda J Butros; Amy Chadburn; Beate Heissig; W Marks; Larry Witte; Y Wu; Daniel J Hicklin; Z Zhu; Neil R Hackett; Helen-Ann Brown Epstein; Malcolm A S Moore; K A Hajjar; Katia Manova-Todorova; Robert Benezra; Shahin Rafii
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.
Nature medicine 2001;7(11):1194-201.
2001: Sergio Dias; Koichi Hattori; Beate Heissig; Z Zhu; Y Wu; Larry Witte; Daniel J Hicklin; M Tateno; Peter Bohlen; Malcolm A S Moore; Shahin Rafii
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(19):10857-62.
2001: RM Shaheen; Syed A Ahmad; Wenbiao Liu; Niels Reinmuth; Young D Jung; WW Tseng; KE Drazan; Corazon D Bucana; Daniel J Hicklin; Lee M Ellis
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
British journal of cancer 2001;85(4):584-9.
2001: Alicia Viloria-Petit; T Crombet; Serge Jothy; Daniel J Hicklin; Peter Bohlen; J M Schlaeppi; Janusz Rak; Robert S Kerbel
Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Cancer research 2001;61(13):5090-101.
2001: K Hattori; Sergio Dias; Beate Heissig; Neil R Hackett; David Lyden; M Tateno; Daniel J Hicklin; Z Zhu; Larry Witte; R G Crystal; Malcolm A S Moore; Shahin Rafii
Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells.
The Journal of experimental medicine 2001;193(9):1005-14.
2001: Peter Carmeliet; Lieve Moons; Aernout Luttun; V Vincenti; Veerle Compernolle; Maria De Mol; Y Wu; Françoise Bono; Laetitia Devy; Heike Beck; Dimitri Scholz; Till Acker; T DiPalma; Mieke Dewerchin; Agnès Noel; Ingeborg Stalmans; A Barra; Silvia Blacher; Thierry VandenDriessche; A Ponten; Ulf Eriksson; Karl H Plate; Jean-Michel Foidart; Wolfgang Schaper; D S Charnock-Jones; Daniel J Hicklin; Jean-Marc Herbert; Désiré Collen; M Graziella Persico
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Nature medicine 2001;7(5):575-83.
2001: Hitoshi Yoshiji; Shigeki Kuriyama; Daniel J Hicklin; James Huber; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Toshiya Nakatani; Hirohisa Tsujinoue; Hiroshi Fukui
The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.
Hepatology (Baltimore, Md.) 2001;33(4):841-7.
2001: Monica Corada; Fang Liao; M Lindgren; Maria Grazia Lampugnani; Ferruccio Breviario; R Frank; W A Muller; Daniel J Hicklin; Peter Bohlen; Elisabetta Dejana
Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability.
Blood 2001;97(6):1679-84.
2001: RM Shaheen; WW Tseng; R Vellagas; Wenbiao Liu; Syed A Ahmad; Young D Jung; Niels Reinmuth; KE Drazan; Corazon D Bucana; Daniel J Hicklin; Lee M Ellis
Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
International journal of oncology 2001;18(2):221-6.
2001: Sergey V Kozin; Yves Boucher; Daniel J Hicklin; P Bohlen; Rakesh K Jain; Herman D Suit
Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
Cancer research 2001;61(1):39-44.
2000: Fang Liao; Yiwen Li; W O'Connor; Lucia Zanetta; Rajiv Bassi; Angel Santiago; Jay Overholser; Andrea T Hooper; Paolo Mignatti; Elisabetta Dejana; Daniel J Hicklin; Peter Bohlen
Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.
Cancer research 2000;60(24):6805-10.
2000: Keji Inoue; Joel W Slaton; Paul Perrotte; Darren W Davis; Christiane J Bruns; Daniel J Hicklin; David J McConkey; Paul Sweeney; Robert Radinsky; Colin P N Dinney
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4874-84.
2000: N Hansen-Algenstaedt; Brian R Stoll; Timothy P Padera; Dennis E J G J Dolmans; Daniel J Hicklin; Dai Fukumura; Rakesh K Jain
Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy.
Cancer research 2000;60(16):4556-60.
2000: Sergio Dias; K Hattori; Z Zhu; Beate Heissig; Margaret Choy; William Stratton Lane; Y Wu; Amy Chadburn; Elizabeth Hyjek; M Gill; Daniel J Hicklin; Larry Witte; Malcolm A S Moore; Shahin Rafii
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.
The Journal of clinical investigation 2000;106(4):511-21.
2000: Christiane J Bruns; Wenbiao Liu; Darren W Davis; RM Shaheen; David J McConkey; M R Wilson; Corazon D Bucana; Daniel J Hicklin; Lee M Ellis
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Cancer 2000;89(3):488-99.
2000: Keji Inoue; Joel W Slaton; Darren W Davis; Daniel J Hicklin; David J McConkey; Takashi Karashima; Robert Radinsky; Colin P N Dinney
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2635-43.
2000: Jay Overholser; Marie Prewett; Andrea T Hooper; Harlan W Waksal; Daniel J Hicklin
Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Cancer 2000;89(1):74-82.
2000: Benjamin Stoelcker; Bernd Echtenacher; Herbert A Weich; H Sztajer; Daniel J Hicklin; Daniela N Männel
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2000;20(5):511-7.
2000: Christiane J Bruns; Matthew T Harbison; Darren W Davis; Charles Portera; Rachel Tsan; David J McConkey; Douglas B Evans; James L Abbruzzese; Daniel J Hicklin; Robert Radinsky
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1936-48.
2000: Giannoula Klement; Sylvain Baruchel; Janusz Rak; Shan Man; K Clark; Daniel J Hicklin; Peter Bohlen; Robert S Kerbel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
The Journal of clinical investigation 2000;105(8):R15-24.
2000: M Peichev; A J Naiyer; D Pereira; Z Zhu; William J Lane; M Williams; Mehmet C Oz; Daniel J Hicklin; Larry Witte; Malcolm A S Moore; Shahin Rafii
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.
Blood 2000;95(3):952-8.
1999: BK Zebrowski; S Yano; Wenbiao Liu; RM Shaheen; Daniel J Hicklin; Joe B Putnam; Lee M Ellis
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3364-8.
1999: Hitoshi Yoshiji; Shigeki Kuriyama; Daniel J Hicklin; James Huber; Junichi Yoshii; Y Miyamoto; M Kawata; Yasuhide Ikenaka; Toshiya Nakatani; Hirohisa Tsujinoue; Hiroshi Fukui
KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Hepatology (Baltimore, Md.) 1999;30(5):1179-86.
1999: Marie Prewett; J Huber; Yiwen Li; Angel Santiago; W O'Connor; K King; Jay Overholser; Andrea T Hooper; Bronislaw Pytowski; Larry Witte; Peter Bohlen; Daniel J Hicklin
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Cancer research 1999;59(20):5209-18.
1999: Zhenping Zhu; Dan Lu; Helen Kotanides; Angel Santiago; Xenia Jimenez; T Simcox; Daniel J Hicklin; Peter Bohlen; Larry Witte
Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.
Cancer letters 1999;136(2):203-13.
1999: Paul Perrotte; T Matsumoto; Keji Inoue; H Kuniyasu; Beryl Y Eve; Daniel J Hicklin; Robert Radinsky; Colin P N Dinney
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):257-65.
1998: Marie Prewett; M Rothman; Harlan W Waksal; M Feldman; N H Bander; Daniel J Hicklin
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(12):2957-66.
1998: Zhenping Zhu; P Rockwell; Dan Lu; Helen Kotanides; Bronislaw Pytowski; Daniel J Hicklin; Peter Bohlen; Larry Witte
Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
Cancer research 1998;58(15):3209-14.
1998: Larry Witte; Daniel J Hicklin; Zhenping Zhu; Bronislaw Pytowski; Helen Kotanides; P Rockwell; P Böhlen
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
Cancer metastasis reviews 1998;17(2):155-61.